Publication
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
Ackerman SE, et al., Nature Cancer (2020)
Publication
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 San Antonio Breast Cancer Symposium
Sharma 2020 poster
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
Ackerman 2020 poster
Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcγR- and TLR- signaling and enables safe systemic administration
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
LeBlanc 2020 poster
Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
Publication
HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner
Presented at: 2019 Society for Immunotherapy of Cancer (SITC)
Publication
TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity
Presented at: 2019 American Association for Cancer Research (AACR)
Publication
Systemic Immunity is Required for Effective Cancer Immunotherapy
Spitzer MH, et al. Cell (2017)
Publication
Allogenic IgG Combined with Dendritic Cell Stimuli Induce Antitumor T-cell Immunity
Carmi Y, et al. Nature (2015)